Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Tait D. Shanafelt, Victoria Wang, Neil E. Kay, Curtis A. Hanson, Susan M. O'Brien, Jacqueline C. Barrientos, Diane F Jelinek, Esteban Braggio, Jose F. Leis, Cong Christina Zhang, Steven Coutre, Paul M. Barr, Amanda F Cashen, Anthony R. Mato, Avina Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark Litzow, Martin S. Tallman
Institutions: Stanford University, Harvard University, Mayo Clinic, University of California, Irvine, University of California, Irvine Medical Center, UC Irvine Chao Family Comprehensive Cancer Center, Hofstra University, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Mayo Clinic in Arizona, Mayo Clinic Hospital, Kaiser Permanente, Kaiser Permanente Oakland Medical Center, Stanford Medicine, University of Rochester Medicine, University of Rochester, Washington University in St. Louis, Memorial Sloan Kettering Cancer Center, Minnesota Oncology, Aurora Health Care, National Institutes of Health, National Cancer Institute, University of Alabama at Birmingham, Dana-Farber Cancer Institute
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2987873401